Neurogene (NGNE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NGNE Neurogene

Watchlist

15.650
+0.320+2.09%

Trading Nov 21 15:29 ET

232.48MMarket Cap-5526P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
Moomoo NewsNov 21 08:31 ET · Ratings
Express News | Neurogene Inc : Stifel Cuts Target Price to $46 From $60
ReutersNov 21 07:21 ET
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $46
Moomoo NewsNov 20 22:31 ET · Ratings
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
Moomoo NewsNov 20 19:31 ET · Ratings
Neurogene's Resilient Clinical Progress and Strong Financial Position Support Buy Rating
TipRanksNov 20 19:15 ET · Ratings
Neurogene Is Maintained at Outperform by BMO Capital
Dow JonesNov 20 09:17 ET · Ratings

Comments

Zz catalyst

Nov 18 22:28

$NGNE 241220 22.50C$ do you notice after trading in the 70+ range for over a year and having an insider sell off. theres some minor bad news but undercover probablymuch worse causing major players to remove there position. Then! you see this a buy offer for fail value price.
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money

Johnny Mnemonic

Nov 18 08:35

if it holds it will fall to 18.50

Stock_Drift

Nov 4 14:44

Unusual Volume Ticks close to close. 4:42pm

$Kazia Therapeutics (KZIA.US)$ $Disc Medicine (IRON.US)$ $Air Transport Services (ATSG.US)$ $Globalstar (GSAT.US)$ $Tenaya Therapeutics (TNYA.US)$ $BIOSIG TECHNOLOGIES INC (BSGM.US)$ $Hanryu Holdings (HRYU.US)$ $Vast Renewables (VSTE.US)$ $Neurogene (NGNE.US)$ $Advent Technologies (ADN.US)$ $Staffing 360 Solutions (STAF.US)$ $Nuwellis (NUWE.US)$ $Simpple (SPPL.US)$
📊⚡️📊

Tarzanman™

Nov 4 11:28

$Neurogene (NGNE.US)$ this shud b 50 or less I'm shorting

Jaguar8

Apr 22 15:37

$Neurogene (NGNE.US)$
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

NGNE Neurogene

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target